A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
PHASE2CompletedINTERVENTIONAL
Enrollment
5
Participants
Timeline
Start Date
September 30, 2015
Primary Completion Date
February 29, 2020
Study Completion Date
February 29, 2020
Conditions
Metastatic Breast Cancer
Interventions
DRUG
Poziotinib
12mg P.O. for 2wks q21days
Trial Locations (1)
135-710
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02544997 - A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway | Biotech Hunter | Biotech Hunter